vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Forestar Group Inc.（FOR）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.7倍（$273.0M vs $156.4M），Forestar Group Inc.同比增速更快（9.0% vs 7.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -9.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
BCRX vs FOR — 直观对比
营收规模更大
FOR
是对方的1.7倍
$156.4M
营收增速更快
FOR
高出1.6%
7.5%
两年增速更快
BCRX
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $273.0M |
| 净利润 | — | $15.4M |
| 毛利率 | — | 20.1% |
| 营业利润率 | 13.6% | 7.6% |
| 净利率 | — | 5.6% |
| 营收同比 | 7.5% | 9.0% |
| 净利润同比 | — | -6.7% |
| 每股收益（稀释后） | $0.00 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXFOR
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $273.0M | ||
| Q3 25 | $159.4M | $670.5M | ||
| Q2 25 | $163.4M | $390.5M | ||
| Q1 25 | $145.5M | $351.0M | ||
| Q4 24 | $131.5M | $250.4M | ||
| Q3 24 | $117.1M | $551.3M | ||
| Q2 24 | $109.3M | $318.4M |
净利润BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $15.4M | ||
| Q3 25 | $12.9M | $86.9M | ||
| Q2 25 | $5.1M | $32.9M | ||
| Q1 25 | $32.0K | $31.6M | ||
| Q4 24 | $-26.8M | $16.5M | ||
| Q3 24 | $-14.0M | $81.5M | ||
| Q2 24 | $-12.7M | $38.7M |
毛利率BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 20.1% | ||
| Q3 25 | 98.6% | 22.3% | ||
| Q2 25 | 98.3% | 20.4% | ||
| Q1 25 | 96.9% | 22.6% | ||
| Q4 24 | 95.4% | 22.0% | ||
| Q3 24 | 97.3% | 23.9% | ||
| Q2 24 | 98.4% | 22.5% |
营业利润率BCRXFOR
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 7.6% | ||
| Q3 25 | 18.6% | 16.9% | ||
| Q2 25 | 18.2% | 11.2% | ||
| Q1 25 | 14.6% | 11.6% | ||
| Q4 24 | -3.4% | 8.7% | ||
| Q3 24 | 6.6% | 19.7% | ||
| Q2 24 | 8.0% | 16.2% |
净利率BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 5.6% | ||
| Q3 25 | 8.1% | 13.0% | ||
| Q2 25 | 3.1% | 8.4% | ||
| Q1 25 | 0.0% | 9.0% | ||
| Q4 24 | -20.4% | 6.6% | ||
| Q3 24 | -12.0% | 14.8% | ||
| Q2 24 | -11.6% | 12.2% |
每股收益（稀释后）BCRXFOR
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.30 | ||
| Q3 25 | $0.06 | $1.70 | ||
| Q2 25 | $0.02 | $0.65 | ||
| Q1 25 | $0.00 | $0.62 | ||
| Q4 24 | $-0.13 | $0.32 | ||
| Q3 24 | $-0.07 | $1.59 | ||
| Q2 24 | $-0.06 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $211.7M |
| 总债务越低越好 | — | $793.2M |
| 股东权益账面价值 | — | $1.8B |
| 总资产 | $465.1M | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
现金及短期投资BCRXFOR
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $211.7M | ||
| Q3 25 | $212.9M | $379.2M | ||
| Q2 25 | $260.0M | $189.2M | ||
| Q1 25 | $295.1M | $174.3M | ||
| Q4 24 | $320.9M | $132.0M | ||
| Q3 24 | $96.8M | $481.2M | ||
| Q2 24 | $78.4M | $359.2M |
总债务BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | — | $793.2M | ||
| Q3 25 | — | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M |
股东权益BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $1.8B | ||
| Q3 25 | $-387.9M | $1.8B | ||
| Q2 25 | $-421.6M | $1.7B | ||
| Q1 25 | $-451.9M | $1.6B | ||
| Q4 24 | $-475.9M | $1.6B | ||
| Q3 24 | $-468.6M | $1.6B | ||
| Q2 24 | $-475.6M | $1.5B |
总资产BCRXFOR
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $3.2B | ||
| Q3 25 | $446.4M | $3.1B | ||
| Q2 25 | $457.2M | $3.1B | ||
| Q1 25 | $480.0M | $3.0B | ||
| Q4 24 | $490.4M | $3.0B | ||
| Q3 24 | $491.3M | $2.8B | ||
| Q2 24 | $472.4M | $2.7B |
负债/权益比BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-157.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-157.1M |
| 自由现金流率自由现金流/营收 | — | -57.5% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | -10.19× |
| 过去12个月自由现金流最近4个季度 | — | $93.0M |
8季度趋势，按日历期对齐
经营现金流BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $-157.0M | ||
| Q3 25 | $41.6M | $256.3M | ||
| Q2 25 | $41.3M | $15.8M | ||
| Q1 25 | $-27.5M | $-19.8M | ||
| Q4 24 | $-5.2M | $-450.0M | ||
| Q3 24 | $8.2M | $119.2M | ||
| Q2 24 | $-1.4M | $-61.7M |
自由现金流BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $-157.1M | ||
| Q3 25 | $40.3M | $255.6M | ||
| Q2 25 | $41.1M | $15.0M | ||
| Q1 25 | $-27.7M | $-20.5M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | $118.4M | ||
| Q2 24 | $-1.5M | $-62.3M |
自由现金流率BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | -57.5% | ||
| Q3 25 | 25.3% | 38.1% | ||
| Q2 25 | 25.2% | 3.8% | ||
| Q1 25 | -19.0% | -5.8% | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | 21.5% | ||
| Q2 24 | -1.4% | -19.6% |
资本支出强度BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 0.5% | 0.0% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.2% |
现金转化率BCRXFOR
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | -10.19× | ||
| Q3 25 | 3.23× | 2.95× | ||
| Q2 25 | 8.12× | 0.48× | ||
| Q1 25 | -859.91× | -0.63× | ||
| Q4 24 | — | -27.27× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | -1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
